In addition, clinical evaluation of Pt.1 with a de novo 1 Mb deletion revealed developmental regression and ASD, whereas features of Pt.3 who carries a LOF point mutation in ARGLU1 included abnormal movement, cerebellar hypoplasia, and oculomotor apraxia. Here, ZNF77 is linked to Oculomotor apraxia.